RHEACELL announces FDA approval for Phase 3 study in refractory, non-curable CVU announced

FDA approved blinded, multi-centric Phase-3 trial (NCTsrc6489src28) to investigate the safety and efficacy of allo-APZ2-CVU in patients with CVU…
Read More

About Author

Stephania Culton

See author's posts

RHEACELL announces FDA approval for Phase 3 study in refractory, non-curable CVU announced

About Author

Stephania Culton

Researchers zero in on genetic variant tied to miscarriages

Cities, states say they’ll need more help to replace millions of lead pipes

Nationwide, couple-based reproductive carrier screening program demonstrates feasibility

Cytomos raises $5m to scale up cell analysis technology production

Researchers zero in on genetic variant tied to miscarriages

Cities, states say they’ll need more help to replace millions of lead pipes

Nationwide, couple-based reproductive carrier screening program demonstrates feasibility

Study assesses risk for 28-day hospitalization for adults with RSV

More than half of people who use party drugs take ADHD medicines without a prescription, new research shows

What Happened on Tulsa King? Here’s Our Recap of Season 2, Episode 2.

The Best Prescription for Safety in Pharmacy

Americans can order free COVID-19 tests beginning this month

Is it a cold, flu or COVID? An expert helps you sort it out

Cytomos raises $5m to scale up cell analysis technology production

Researchers zero in on genetic variant tied to miscarriages

Cities, states say they’ll need more help to replace millions of lead pipes

Nationwide, couple-based reproductive carrier screening program demonstrates feasibility

Study assesses risk for 28-day hospitalization for adults with RSV

About PhaMed

Recent News

About Author

More Stories

You may have missed

About PhaMed

Recent News

Categories